CORDIS
EU research results

CORDIS

English EN

Role of Ubiquitin and Ubiquitin-like Modifiers in Cellular Regulation

Project information

Grant agreement ID: 18683

  • Start date

    1 January 2006

  • End date

    30 June 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 12 000 001

  • EU contribution

    € 12 000 000

Coordinated by:

KAROLINSKA INSTITUTET

Sweden

Objective

Our objective is to create the conditions for the rapid progress of research on the molecular principles of post-translational modifications of proteins by linkage of ubiquitin and ubiquitin-like molecules, the regulatory role of such modifications in basi c biological processes and their implications for pathological conditions that represent urgent socio-economic and human needs such as chronic inflammation, neurodegeneration and cancer. The RUBICON consortium will take a multi-disciplinary and multifacet ed approach to these problems. To enhance interdisciplinary research, RUBICON brings together investigators from different backgrounds that will work at all levels of a drug discovery oriented process. The organisation of the Joint Programme infrastructure s include shared RUBICON-funded core facilities and a web database serving as a European repository for biological research tools. Training will be provided by: a competitive programme of multi-centre postdoctoral fellowships, by mobility of scientists to RUBICON centres and platforms, and by open-lab meetings, summer schools and workshops. To feed back the benefits of integration into EU society, we have identified associated research groups and will open network meetings and fellowship programs to young investigators and scientists from new European countries. We aim to integrate research efforts within the first 18 months of the project, and then build on the infrastructure and collaborations established in order to enhance the competitiveness of Europea n research on ubiquitin and ubiquitin-like modifications, and promote, in concert with SMEs, the emergence of novel mechanism-based therapeutic approaches to diseases associated with disturbance of these basic regulatory processes.

Coordinator

KAROLINSKA INSTITUTET

Address

Nobels VÄG 5
Stockholm

Sweden

Participants (22)

THE NETHERLANDS CANCER INSTITUTE/ANTONI VAN LEEUWENHOEK HOSPITAL

Netherlands

UNIVERSITY MEDICAL CENTER

Netherlands

MEDICAL RESEARCH COUNCIL

United Kingdom

UNIVERSITY OF DUNDEE

United Kingdom

INSTITUT PASTEUR

France

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

MAX PLANCK SOCIETY FOR THE ADVANCEMENT OF SCIENCE

Germany

BEREICH HUMANMEDIZIN DER GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS -

Germany

MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN

Germany

IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE

Italy

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

Israel

THE HEBREW UNIVERSITY OF JERUSALEM

Israel

PEPSCAN SYSTEMS B.V.

Netherlands

DRUG DISCOVERY FACTORY BV

Netherlands

PROTEOLOGICS LTD

Israel

PEPSCAN THERAPEUTICS BV

Netherlands

ENZO LIFE SCIENCES LTD

United Kingdom

RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

Germany

SA CYTOMICS PHARMACEUTICALS

France

UNIVERSITÄT KONSTANZ

Germany

UNIVERSITÄT STUTTGART

Germany

UNIVERSITÄT ZU KÖLN

Germany

Project information

Grant agreement ID: 18683

  • Start date

    1 January 2006

  • End date

    30 June 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 12 000 001

  • EU contribution

    € 12 000 000

Coordinated by:

KAROLINSKA INSTITUTET

Sweden